General Information

Institutional Information: Faculty Of Medicine, Department Of Basic Medical Sciences, Medical Department Of Biology
Research Areas: Medicine, Medical Biology, Internal Medicine Sciences, Medical Genetics, Health Sciences, Fundamental Medical Sciences




Citation (WoS)


H-Index (WoS)


Citation (Scopus)


H-Index (Scopus)


Citation (Scholar)


H-Index (Scholar)


Citiation (TrDizin)




Intellectual Property


Thesis Advisory


Open Access

UN Sustainable Development Goals


A Short Biography of Salih Sanlioglu VMD, PhD:


Following his graduation from the School of Veterinary Medicine at Selcuk University in Turkiye, Salih Sanlioglu, VMD, PhD, pursued further studies at the Ohio State University College of Medicine, where he successfully earned both his Master's (1992) and PhD (1996) degrees in the field of Molecular Cell Biology and Genetics. After completing his postdoctoral training at the Human Gene Therapy Institute of the University of Pennsylvania in 1997 and an internal medicine research fellowship at the Gene Therapy Center of the University of Iowa in 2002, Dr. Sanlioglu joined the medical faculty at Akdeniz University in Antalya, Turkiye. There, he established the country's inaugural human gene and cell therapy facility, which can be accessed at

His initial research efforts in gene therapy were primarily focused on comprehending the mechanisms of Adeno Associated Virus (AAV) gene delivery into cells, resulting in publications featured on the covers of the Journal of Virology and Virology Journal. Subsequently, he made significant strides by using adenoviruses to transport genes encoding death ligands (TRAIL) for cancer treatment, garnering attention from journals such as Cancer Gene Therapy and Human Gene Therapy, among others.

Dr. Sanlioglu also demonstrated the feasibility of using adenovirus vectors to reprogram pancreatic islets for potential use in cell therapy studies for Type 1 diabetes. Given the gravity of diabetes as a disease suitable for gene therapy, he adopted the third generation of lentiviral vectors for delivering anti-diabetic genes to experimental subjects with obesity and diabetes. These vectors were chosen for their capacity to provide long-term gene expression without adverse effects. His groundbreaking research on gene therapy for diabetes appeared on the covers of Human Gene Therapy and Nature Gene Therapy Journal.

Furthermore, his recent research interests have extended to viral-mediated therapeutic gene delivery for preventing retinal degeneration in the diseased eye. Dr. Sanlioglu has also utilized gene editing technology, including CRISPR/Cas9, to rectify disease-causing mutations. He also holds an interest in the development of potent viral vector-based gene therapy vaccines aimed at combating pandemic infectious diseases like COVID-19.

Currently, Dr. Sanlioglu serves as the director of the Center for Gene and Cell Therapy and heads the newly established Department of Gene and Cell Therapy at Akdeniz University. His exemplary contributions continue to shape the field of gene therapy.


Web Page
Office Phone
+90 242 227 4401 Extension: 3898
Office Phone
+90 242 227 4401 Extension: 3897
Gen ve Hücre Tedavi Merkezi Laboratuvar Binasi 2. Kat
Akdeniz Üniversitesi Gen ve Hücre Tedavi Merkez Laboratuvar Binasi 2. Kat Kampüs Antalya, 07058